Exhibit 99.1 Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing – — Additional data from the ongoing Phase 2 TRANQUILITY trial to be presented at the European Society of Cardiology Congress in August 2025 – NEW YORK – August 13, 2025 – Tourmaline Bio, I ...